Belantamab mafodotin Clinical Trials
10 recruitingDrug
Phase 28Phase 15Phase 31
Showing 1–10 of 10 trials
Recruiting
Phase 2
A Study to Evaluate the Efficacy and Safety of Belantamab Mafodotin in Combination With Standard of Care in Participants With Relapsed-Refractory Multiple Myeloma (RRMM)
Multiple Myeloma
GlaxoSmithKline200 enrolled6 locationsNCT07227311
Recruiting
Phase 3
A Study of Belantamab Mafodotin Administered in Combination With Lenalidomide and Dexamethasone (BRd) Versus Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Participants With Newly Diagnosed Multiple Myeloma (NDMM) Who Are Ineligible for Autologous Stem Cell Transplantation (TI-NDMM)
Multiple MyelomaNewly Diagnosed Multiple Myeloma
GlaxoSmithKline520 enrolled181 locationsNCT06679101
Recruiting
Phase 1Phase 2
Isatuximab in Combination With Novel Agents in RRMM - Master Protocol
Plasma Cell Myeloma Refractory
Sanofi258 enrolled28 locationsNCT04643002
Recruiting
Phase 2
Minimal Residual Disease Guided Maintenance Therapy With Belantamab Mafodotin and Lenalidomide After Autologous Hematopoietic Cell Transplantation in Patients With Newly Diagnosed Multiple Myeloma
M.D. Anderson Cancer Center94 enrolled1 locationNCT05091372
Recruiting
Phase 1Phase 2
A Study to Investigate the Safety and Efficacy of Belantamab for the Treatment of Multiple Myeloma When Used as Monotherapy and in Combination Treatments
Multiple Myeloma
GlaxoSmithKline153 enrolled27 locationsNCT05714839
Recruiting
Phase 2
Isatuximab, Bela Maf, Pom, and Dex in Relapsed/Refractory Multiple Myeloma
Multiple MyelomaRelapsed CancerRefractory Multiple Myeloma
Massachusetts General Hospital50 enrolled2 locationsNCT05922501
Recruiting
Phase 2
Study of Belantamab Mafodotin With Carfilzomib, Pomalidomide, and Dexamethasone in Relapsed Multiple Myeloma
Multiple MyelomaRelapse Multiple Myeloma
University of Chicago83 enrolled1 locationNCT05789303
Recruiting
Phase 1
A Phase 1 With Extension Cohort, Single Arm, Single Center, Open Label Trial of Belantamab Mafodotin for the Treatment of High-Risk Smoldering Multiple Myeloma
Myeloma
M.D. Anderson Cancer Center30 enrolled1 locationNCT05055063
Recruiting
Phase 1Phase 2
Novel Combination of Belantamab Mafodotin and Elotuzumab to Enhance Therapeutic Efficacy in Multiple Myeloma
Multiple Myeloma
Yale University24 enrolled1 locationNCT05002816
Recruiting
Phase 1Phase 2
Study of Belantamab Mafodotin in Combination With Kd for the Treatment of Relapsed Myeloma Patients, Refractory to Lenalidomide
Relapsed Multiple Myeloma
PETHEMA Foundation60 enrolled15 locationsNCT05060627